Numis Has Just Reaffirmed GBX 55.00 Target Price Per Share on Hvivo (LON:HVO) stock, While They’ve Also Reiterated Their Buy Rating

June 18, 2018 - By Vivian Park

hVIVO plc (LON:HVO) Logo

Hvivo (LON:HVO) Rating Reaffirmed

In analysts note sent to investors on Monday, 18 June, The Buy rating of Hvivo (LON:HVO) shares was reiterated by Numis, who now has a GBX 55.00 PT on the stock. Numis’s PT means a possible upside of 113.18 % from the last stock close price of the company.

The stock increased 30.71% or GBX 6.05 during the last trading session, reaching GBX 25.75. About 477,852 shares traded or 240.46% up from the average. hVIVO plc (LON:HVO) has 0.00% since June 18, 2017 and is . It has underperformed by 12.57% the S&P500.

hVIVO plc, a specialty biopharma company, provides medical and scientific research services in the United Kingdom. The company has market cap of 20.14 million GBP. It is developing a human analytical platform to accelerate drug discovery and development in respiratory and infectious diseases, including flu, RSV, asthma, exacerbation, and common cold. It currently has negative earnings. The firm also offers laboratory based research services; and target and biomarker discovery services.

Another recent and important hVIVO plc (LON:HVO) news was published by Equitiesfocus.com which published an article titled: “Equities Research Analysts’ Updated EPS Estimates for June, 6th (AZN, BDEV, BT.A, FORT, HNT, HVO, KEYS, KLIC …” on June 06, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: